Results 91 to 100 of about 19,378,005 (296)

Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients

open access: yes, 2011
Evaluation of: Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822–1826 (2011). Chimeric antigen receptor (CAR)-T cells
Kimberley Jones, Maher Gandhi
core   +1 more source

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report

open access: yesJournal of Medical Case Reports
Background Mantle cell lymphoma is a diverse B-cell lymphoma with varying clinical behaviors. Treating relapsed or refractory mantle cell lymphoma is challenging, with Bruton’s tyrosine kinase inhibitors proving effective but not curative.
G. Menardi   +7 more
doaj   +1 more source

Chimeric antigen receptor modified T-cells for cancer treatment

open access: yesChronic Diseases and Translational Medicine, 2018
T cells engineered with the chimeric antigen receptor (CAR) are rapidly emerging as an important immunotherapy for hematologic malignancies. The anti-cluster of differentiation (CD)19 CAR-T cell therapy has been remarkably successful against refractory ...
Xiao Han, Yao Wang, Wei-Dong Han
doaj   +1 more source

Magnetically Guided Macrophage Immunobots Coordinate Iron‐Metabolic Cascades and Immunogenic Ferroptosis for Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
Magnetically guided macrophage immunobots integrate active tumor targeting with immunometabolic therapy. After systemic administration, magnetic actuation enhances immunobot retention and tumor penetration, while LPS‐functionalized FePt microrollers sustain M1‐like polarization through inflammatory and iron‐amplified oxidative signaling and trigger ...
Xirui Zeng   +7 more
wiley   +1 more source

sj-pdf-1-aop-10.1177_10600280211026338 – Supplemental material for Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma

open access: yes, 2021
Supplemental material, sj-pdf-1-aop-10.1177_10600280211026338 for Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma by Mary Kate Anderson, Annie Torosyan and Zachery Halford in Annals of
Annie Torosyan (11256987)   +2 more
core   +1 more source

Chimeric antigen receptor T-cell therapy and bispecific antibodies in the treatment of lymphoma for human immunodeficiency virus-infected patients: A systematic review

open access: yesSAGE Open Medicine
Background: Chimeric antigen receptor T-cell therapy has emerged as a highly effective treatment for relapsed and refractory lymphomas; however, its application in individuals with human immunodeficiency virus remains underexplored.
Alejandra Viera Plasencia   +6 more
doaj   +1 more source

Chimeric Antigen Receptor—Macrophages in Pancreatic Cancer: Promise, Pitfalls, and the Path Ahead

open access: yesFrontiers in Bioscience-Elite
Chimeric antigen receptor–engineered macrophages (CAR-Ms) are emerging as a transformative frontier in immunotherapy and represent a promising strategy for pancreatic cancer.
Palloma Porto Almeida   +1 more
doaj   +1 more source

Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

open access: yesNature Communications, 2019
Supraphysiological T cell activation by chimeric antigen receptor (CAR) contributes to T cell exhaustion and adverse events in CAR T cell therapies. Here the authors engineer a synthetic antigen receptor that integrates into the endogenous TCR complex ...
Patrick A. Baeuerle   +20 more
doaj   +1 more source

Chimeric antigen receptor T-cell therapy [PDF]

open access: yesIndian Journal of Medical and Paediatric Oncology, 2020
Azgar Abdul Rasheed   +1 more
openaire   +1 more source

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

open access: yesAdvanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy